Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.

Clinical pharmacology and therapeutics - 1 Jul 2000

Labbé L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J

Abstract excerpt

BACKGROUND AND OBJECTIVE: Mexiletine and propafenone are often used concomitantly and are metabolized by the same cytochrome P450 isozymes, namely CYP2D6, CYP1A2, and probably CYP3A4. Our objective was to study the potential pharmacokinetic and electrophysiological interactions between mexiletine and propafenone. METHODS: Fifteen healthy volunteers, 8 extensive metabolizers and 7 poor metabolizers of CYP2D6,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP3A

Share to Drug Administration Schedule

Share to Electrocardiography

Share to Mixed Function Oxygenases

Source

Identifiers

PMID: 10945315
DOI: 10.1067/mcp.2000.108023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.PMID 10945315Read ↗

The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.Semantic proximity Read ↗

Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.Semantic proximity Read ↗

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.Semantic proximity Read ↗

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.Semantic proximity Read ↗

CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.Semantic proximity Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.Semantic proximity Read ↗

Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.Semantic proximity Read ↗

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.